Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).
Antiosteoporosis medication (AOM) does not abolish fracture risk, and some individuals experience multiple fractures while on treatment. Therefore, criteria for treatment failure have recently been defined. Using data from the Global Longitudinal Study of Osteoporosis in Women (GLOW), we analyzed ri...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|
| _version_ | 1797075356266528768 |
|---|---|
| author | Díez-Pérez, A Adachi, J Adami, S Anderson, F Boonen, S Chapurlat, R Compston, J Cooper, C Gehlbach, S Greenspan, S Hooven, F LaCroix, A Nieves, J Netelenbos, J Pfeilschifter, J Rossini, M Roux, C Saag, K Silverman, S Siris, E Wyman, A Rushton-Smith, S Watts, N |
| author_facet | Díez-Pérez, A Adachi, J Adami, S Anderson, F Boonen, S Chapurlat, R Compston, J Cooper, C Gehlbach, S Greenspan, S Hooven, F LaCroix, A Nieves, J Netelenbos, J Pfeilschifter, J Rossini, M Roux, C Saag, K Silverman, S Siris, E Wyman, A Rushton-Smith, S Watts, N |
| author_sort | Díez-Pérez, A |
| collection | OXFORD |
| description | Antiosteoporosis medication (AOM) does not abolish fracture risk, and some individuals experience multiple fractures while on treatment. Therefore, criteria for treatment failure have recently been defined. Using data from the Global Longitudinal Study of Osteoporosis in Women (GLOW), we analyzed risk factors for treatment failure, defined as sustaining two or more fractures while on AOM. GLOW is a prospective, observational cohort study of women aged ≥55 years sampled from primary care practices in 10 countries. Self-administered questionnaires collected data on patient characteristics, fracture risk factors, previous fractures, AOM use, and health status. Data were analyzed from women who used the same class of AOM continuously over 3 survey years and had data available on fracture occurrence. Multivariable logistic regression was used to identify independent predictors of treatment failure. Data from 26,918 women were available, of whom 5550 were on AOM. During follow-up, 73 of 5550 women in the AOM group (1.3%) and 123 of 21,368 in the non-AOM group (0.6%) reported occurrence of two or more fractures. The following variables were associated with treatment failure: lower Short Form 36 Health Survey (SF-36) score (physical function and vitality) at baseline, higher Fracture Risk Assessment Tool (FRAX) score, falls in the past 12 months, selected comorbid conditions, prior fracture, current use of glucocorticoids, need of arms to assist to standing, and unexplained weight loss ≥10 lb (≥4.5 kg). Three variables remained predictive of treatment failure after multivariable analysis: worse SF-36 vitality score (odds ratio [OR] per 10-point increase, 0.85; 95% confidence interval [CI], 0.76-0.95; p = 0.004); two or more falls in the past year (OR, 2.40; 95% CI, 1.34-4.29; p = 0.011), and prior fracture (OR, 2.93; 95% CI, 1.81-4.75; p < 0.0001). The C statistic for the model was 0.712. Specific strategies for fracture prevention should therefore be developed for this subgroup of patients. |
| first_indexed | 2024-03-06T23:49:18Z |
| format | Journal article |
| id | oxford-uuid:720878f5-a933-49e1-8410-b016b2f75d0d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:49:18Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:720878f5-a933-49e1-8410-b016b2f75d0d2022-03-26T19:47:39ZRisk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:720878f5-a933-49e1-8410-b016b2f75d0dEnglishSymplectic Elements at Oxford2014Díez-Pérez, AAdachi, JAdami, SAnderson, FBoonen, SChapurlat, RCompston, JCooper, CGehlbach, SGreenspan, SHooven, FLaCroix, ANieves, JNetelenbos, JPfeilschifter, JRossini, MRoux, CSaag, KSilverman, SSiris, EWyman, ARushton-Smith, SWatts, NAntiosteoporosis medication (AOM) does not abolish fracture risk, and some individuals experience multiple fractures while on treatment. Therefore, criteria for treatment failure have recently been defined. Using data from the Global Longitudinal Study of Osteoporosis in Women (GLOW), we analyzed risk factors for treatment failure, defined as sustaining two or more fractures while on AOM. GLOW is a prospective, observational cohort study of women aged ≥55 years sampled from primary care practices in 10 countries. Self-administered questionnaires collected data on patient characteristics, fracture risk factors, previous fractures, AOM use, and health status. Data were analyzed from women who used the same class of AOM continuously over 3 survey years and had data available on fracture occurrence. Multivariable logistic regression was used to identify independent predictors of treatment failure. Data from 26,918 women were available, of whom 5550 were on AOM. During follow-up, 73 of 5550 women in the AOM group (1.3%) and 123 of 21,368 in the non-AOM group (0.6%) reported occurrence of two or more fractures. The following variables were associated with treatment failure: lower Short Form 36 Health Survey (SF-36) score (physical function and vitality) at baseline, higher Fracture Risk Assessment Tool (FRAX) score, falls in the past 12 months, selected comorbid conditions, prior fracture, current use of glucocorticoids, need of arms to assist to standing, and unexplained weight loss ≥10 lb (≥4.5 kg). Three variables remained predictive of treatment failure after multivariable analysis: worse SF-36 vitality score (odds ratio [OR] per 10-point increase, 0.85; 95% confidence interval [CI], 0.76-0.95; p = 0.004); two or more falls in the past year (OR, 2.40; 95% CI, 1.34-4.29; p = 0.011), and prior fracture (OR, 2.93; 95% CI, 1.81-4.75; p < 0.0001). The C statistic for the model was 0.712. Specific strategies for fracture prevention should therefore be developed for this subgroup of patients. |
| spellingShingle | Díez-Pérez, A Adachi, J Adami, S Anderson, F Boonen, S Chapurlat, R Compston, J Cooper, C Gehlbach, S Greenspan, S Hooven, F LaCroix, A Nieves, J Netelenbos, J Pfeilschifter, J Rossini, M Roux, C Saag, K Silverman, S Siris, E Wyman, A Rushton-Smith, S Watts, N Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). |
| title | Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). |
| title_full | Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). |
| title_fullStr | Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). |
| title_full_unstemmed | Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). |
| title_short | Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). |
| title_sort | risk factors for treatment failure with antiosteoporosis medication the global longitudinal study of osteoporosis in women glow |
| work_keys_str_mv | AT diezpereza riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT adachij riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT adamis riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT andersonf riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT boonens riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT chapurlatr riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT compstonj riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT cooperc riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT gehlbachs riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT greenspans riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT hoovenf riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT lacroixa riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT nievesj riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT netelenbosj riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT pfeilschifterj riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT rossinim riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT rouxc riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT saagk riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT silvermans riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT sirise riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT wymana riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT rushtonsmiths riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow AT wattsn riskfactorsfortreatmentfailurewithantiosteoporosismedicationthegloballongitudinalstudyofosteoporosisinwomenglow |